Premium
T Cell Antigen Receptor Vaccines for Active Therapy of T Cell Malignancies
Author(s) -
REDDY SUNIL A.,
OKADA CRAIG,
WONG CARMEN,
BAHLER DAVID,
LEVYA RONALD
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb03714.x
Subject(s) - t cell receptor , mycosis fungoides , chimeric antigen receptor , immunotherapy , immunology , medicine , idiotype , t cell , antigen , lymphoproliferative disorders , lymphoma , immune system , antibody , monoclonal antibody
A bstract : T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR‐Id) vaccine because the TCR‐Id can serve as a tumor‐specific antigen. In this article we will briefly review the rationale for TCR‐Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.